Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2165602
Max Phase: Preclinical
Molecular Formula: C10H9ClN2O3S
Molecular Weight: 272.71
Molecule Type: Small molecule
Associated Items:
ID: ALA2165602
Max Phase: Preclinical
Molecular Formula: C10H9ClN2O3S
Molecular Weight: 272.71
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=c1cc(CS(=O)(=O)c2ccc(Cl)cc2)[nH][nH]1
Standard InChI: InChI=1S/C10H9ClN2O3S/c11-7-1-3-9(4-2-7)17(15,16)6-8-5-10(14)13-12-8/h1-5H,6H2,(H2,12,13,14)
Standard InChI Key: YTPVCZIIXMZKHA-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 272.71 | Molecular Weight (Monoisotopic): 272.0022 | AlogP: 1.33 | #Rotatable Bonds: 3 |
Polar Surface Area: 82.79 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 7.75 | CX Basic pKa: | CX LogP: 0.44 | CX LogD: 0.29 |
Aromatic Rings: 2 | Heavy Atoms: 17 | QED Weighted: 0.88 | Np Likeness Score: -1.49 |
1. Chen T, Benmohamed R, Kim J, Smith K, Amante D, Morimoto RI, Kirsch DR, Ferrante RJ, Silverman RB.. (2012) ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis., 55 (1): [PMID:22191331] [10.1021/jm2014277] |
Source(1):